Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review

References

• Bader H, Ringsdorf H. Water soluble polymers in medicine. Angew Makromol Chem. 1984;123/124:457–485.
   Google Scholar
• Yokoyama M. Polymeric micelle drug carriers for tumor targeting. In: Chapter 3, Svenson S, editor. Polymeric drug delivery I: particulate drug carriers. Washington: Oxford University Press; 2006. p. 27–39.
   Google Scholar
• Yokoyama M. Polymeric micelles as a new drug carrier system and their required considerations for clinical trials. Expert Opin Drug Deliv. 2010;7:145–158.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Isacson R, Rosengarten O, et al. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol. 2008;61:695–702.
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Yamamoto T, Yokoyama M, et al. Histological study on side effects and tumor targeting of a block copolymer micelle on rats. J Control Release. 2009;136:240–246.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Yokoyama M, Opanasopit P, et al. What are determining factors for stable drug incorporation into polymeric micelle carriers? Consideration on physical and chemical characters of the micelle inner core. J Control Release. 2007;23:11–18.
   Web of Science ®Google Scholar
• Kawano K, Watanabe M, Yamamoto T, et al. Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. J Control Release. 2006;112:329–:332.
   Web of Science ®Google Scholar
• Chansri N, Kawakami S, Yokoyama M, et al. Anti-tumor effect of all-trans retinoic acid loaded polymeric micelles in solid tumor bearing mice. Pharm Res. 2008;25:428–434.
   PubMed Web of Science ®Google Scholar
• Satoh T, Higuchi Y, Kawakami S, et al. Encapsulation of the synthetic retinoids Am80 and LE540 into polymeric micelles and the retinoids’ release control. J Control Release. 2009;136:187–195.
   PubMed Web of Science ®Google Scholar
• Ivens IA, Achanzar W, Baumann A, et al. PEGylated biopharmaceuticals: current experience and considerations for nonclinical development. Toxicol Pathol. 2015;3:959–983.
   Web of Science ®Google Scholar
• Turecek PL, Bossard MJ, Schoetens F, et al. PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J Pharm Sci. 2016;105:460–475.
   PubMed Web of Science ®Google Scholar
• Knop K, Hoogenboom R, Fischer D, et al. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed. 2010;49:6288–6308.
   PubMed Web of Science ®Google Scholar
• Kang JS, DeLuca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerging Drugs. 2009;14:363–380.
   PubMed Web of Science ®Google Scholar
• Shiraishi K, Sanada Y, Mochizuki S, et al. Determination of polymeric micelles’ structural characteristics, and effect of the characteristics on pharmacokinetic behaviors. J Control Release. 2015;203:77–84.
   PubMed Web of Science ®Google Scholar
• Yang Q, Jones SW, Parker CL, et al. Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation. Mol Pharm. 2014;11:1250–1258.
   PubMed Web of Science ®Google Scholar
• Walkey CD, Olsen JB, Guo H, et al. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc. 2012;134:2139–2147.
   PubMed Web of Science ®Google Scholar
• Perry JL, Reuter KG, Kai MP, et al. Nano Lett. PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett. 2012;12:5304–5310.
   PubMed Web of Science ®Google Scholar
• Sanada Y, Akiba I, Hashida S, et al. Composition dependence of the micellar architecture made from poly(ethylene glycol)-block-poly(partially benzyl-esterified aspartic acid). J Phys Chem B. 2012;116:8241–8250.
   PubMed Web of Science ®Google Scholar
• Abuchowski A, Es TV, Palczuk NC, et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem. 1977;252:3578–3581.
   PubMed Web of Science ®Google Scholar
• Klibanov AL, Maruyama K, Torchilin VP, et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268:235–237.
   PubMed Web of Science ®Google Scholar
• Barenholz YC. Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–134.
   PubMed Web of Science ®Google Scholar
• Lipsky PE, Calabrese LH, Kavanaugh A, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16:R60.
   PubMed Web of Science ®Google Scholar
• Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects peg-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007;10:103–111.
   Web of Science ®Google Scholar
• Ganson NJ, Kelly SJ, Scarlett E, et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther. 2006;8:R12.
   PubMed Web of Science ®Google Scholar
• Longo N, Harding CO, Burton BK, et al. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet. 2014;384:37–44.
   PubMed Web of Science ®Google Scholar
• Hershfield MS, Ganson NJ, Kelly SJ, et al. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res Ther. 2014;16:R63.
   PubMed Web of Science ®Google Scholar
• Garay RP, El-Gewely R, Armstrong JK, et al. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv. 2012;9:1319–1323.
   PubMed Web of Science ®Google Scholar
• Ganson NJ, Povsic TJ, Sullenger BA, et al. Pre-existing anti-PEG antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. J Allergy Clin Immunol. 2016;137:1610–1613.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Gray T. A single dose of intravenously injected poloxamine-coated long-circulating particles triggers macrophage clearance of subsequent doses in rats. Clin Sci. 1997;93:371–379.
   PubMed Web of Science ®Google Scholar
• Dams ETM, Laverman P, Oyen WJG, et al. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharm Exp Ther. 2000;292:1071–1079.
   PubMed Web of Science ®Google Scholar
• Laverman P, Carstens MG, Boerman OC, et al. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharm Exp Ther. 2001;298:607–612.
   PubMed Web of Science ®Google Scholar
• Shiraishi K, Kawano K, Minowa T, et al. Preparation and in vivo imaging of PEG-poly(L-lysine)-based polymeric micelle MRI contrast agents. J Control Release. 2009;136:14–20.
   PubMed Web of Science ®Google Scholar
• Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res. 2013;30:1729–1734.
   PubMed Web of Science ®Google Scholar
• Yang Q, Lai SK. Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Nanomed Nanobiotechnol. 2015;7:655–677.
   Web of Science ®Google Scholar
• Lubich C, Allacher P, de la Rosa M, et al. The mystery of antibodies against polyethylene glycol (PEG): what do we know? Pharm Res. 2016;33:2239–2249.
   PubMed Web of Science ®Google Scholar
• Zhang P, Sun F, Liu S, et al. Anti-PEG antibodies in the clinic: current issues and beyond PEGylation. J Control Release. 2016;244:184–193.
   PubMed Web of Science ®Google Scholar
• Ishida T, Ichiahara M, Wang XY, et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release. 2006;112:15–25.
   PubMed Web of Science ®Google Scholar
• Verhoef JJF, Carpenter JF, Anchordoquy TJ, et al. Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. Drug Discov Today. 2014;19:1945–1952.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Anderson AJ, Ahmadvand A, et al. Material properties in complement activation. Adv Drug Deliv Rev. 2011;63:1000–1007.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hamad I, Andersen TL, et al. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J. 2006;20:2591–2593.
   PubMed Web of Science ®Google Scholar
• Abbas AK, Lichtman AH. Basic immunology: functions and disorders of the immune system. Cambridge (MA): Elsevier; 2006.
   Google Scholar
• Cheng X, Wang C, Su Y, et al. Enhanced opsonization-independent phagocytosis and high response ability to opsonized antigen–antibody complexes: a new role of kupffer cells in the accelerated blood clearance phenomenon upon repeated injection of PEGylated emulsions. Mol Pharm. 2018;15:3755–3766.
   PubMed Web of Science ®Google Scholar
• Moghimi SM. Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth. J Control Release. 2014;190:556–562.
   PubMed Web of Science ®Google Scholar
• La-Beck NM, Gabizon AA. Nanoparticle interactions with the immune system: clinical implications for Liposome-Based cancer chemotherapy. Front Immunol. 2017;8:00416.
   PubMed Web of Science ®Google Scholar
• Ma H, Shiraishi K, Minowa T, et al. Accelerated blood clearance was not induced for a gadolinium-containing PEG-poly(L-lysine)-based polymeric micelle in mice. Pharm Res. 2010;27:296–302.
   PubMed Web of Science ®Google Scholar
• Romberg B, Oussoren C, Snel CJ, et al. Pharmacokinetics of poly(hydroxyethyl-L-asparagine)-coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration. Biochim Biophys Acta. 2007;768:737–743.
   Web of Science ®Google Scholar
• Lila ASA, Nawata K, Shimizu T, et al. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration. Int J Pharm. 2013;456:235–242.
   PubMed Web of Science ®Google Scholar
• Ishihara T, Maeda T, Sakamoto H, et al. Evasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymers. Biomacromolecules. 2010;11:2700–2706.
   PubMed Web of Science ®Google Scholar
• Shiraishi K, Hamano M, Ma H, et al. Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon. J Control Release. 2013;165:183–190.
   PubMed Web of Science ®Google Scholar
• Ishida T, Atobe K, Wang XY, et al. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J Control Release. 2006;115:251–258.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Szebeni J, Savay S, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions. Annal Oncol. 2003;14:1430–1437.
   PubMed Web of Science ®Google Scholar
• Neun BW, Barenholz Y, Szebeni J, et al. Understanding the role of anti-PEG antibodies in the complement activation by Doxil in vitro. Molecules. 2018;23:1700–1718.
   Web of Science ®Google Scholar
• Richter AW, Åkerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Archs Allergy Appl Immun. 1983;70:124–131.
   PubMedGoogle Scholar
• Shiraishi K, Kawano K, Maitani Y, et al. Exploring the relationship between anti-PEG IgM behaviors and PEGylated nanoparticles and its significance for accelerated blood clearance. J Control Release. 2016;234:59–67.
   PubMed Web of Science ®Google Scholar
• Ishida T, Ichihara M, Wang XY, et al. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J Control Release. 2006;115:243–250.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Ishida T, Kiwada H. Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon. Immunobiology. 2015;220:1151–1160.
   PubMed Web of Science ®Google Scholar
• Ishida T, Wang XY, Shimizu T, et al. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release. 2007;122:349–355.
   PubMed Web of Science ®Google Scholar
• Koide H, Asai T, Hatanaka K, et al. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int J Pharm. 2010;392:218–2223.
   PubMed Web of Science ®Google Scholar
• Ichihara M, Shimizu T, Imoto A, et al. Anti-PEG IgM response against PEGylated liposomes in mice and rats. Pharmaceutics. 2011;3:1–11.
   Google Scholar
• Moghimi SM, Anderson AJ, Hashemi SH, et al. Complement activation cascade triggered by PEG–PL engineered nanomedicines and carbon nanotubes: the challenges ahead. J Control Release. 2010;146:175–181.
   PubMed Web of Science ®Google Scholar
• Hamad I, Hunter AC, Moghimi SM. Complement monitoring of Pluronic 127 gel and micelles: suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins AI and B-100. J Control Release. 2013;170:167–174.
   PubMed Web of Science ®Google Scholar
• Devine DV, Wong K, Serrano K, et al. Liposome-complement interactions in rat serum: implications for liposome survival studies. Biochim Biophys Acta. 1994;1191:43–51.
   PubMed Web of Science ®Google Scholar
• Anderson AJ, Robinson JT, Dai H, et al. Single-walled carbon nanotube surface control of complement recognition and activation. ACS Nano. 2013;7:1108–1119.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Simberg D. Complement activation turnover on surfaces of nanoparticles. Nano Today. 2017;15:8–10.
   PubMed Web of Science ®Google Scholar
• Chen F, Wang G, Griffin JI, et al. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. Nat Nanotechnol. 2017;12:387–393.
   PubMed Web of Science ®Google Scholar
• Yu K, Lai BFL, Foley JH, et al. Modulation of complement activation and amplification on nanoparticle surfaces by glycopolymer conformation and chemistry. ACS Nano. 2014;8:7687–7703.
   PubMed Web of Science ®Google Scholar
• Hamad I, Al-Hanbali O, Hunter AC, et al. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano. 2010;4:6629–6638.
   PubMed Web of Science ®Google Scholar
• Ricklin D, Hajishengallis, Yang K, et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–797.
   PubMed Web of Science ®Google Scholar
• Sherman MR, Williams LD, Sobczyk MA, et al. Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconj Chem. 2012;23:485–499.
   PubMed Web of Science ®Google Scholar
• Saifer MGP, Williams LD, Sobczyk MA, et al. Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins. Mol Immunol. 2014;57:236–246.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Lila ASA, Fujita R, et al. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes. Eur J Pharm Biopharm. 2018;127:142–149.
   PubMed Web of Science ®Google Scholar
• Zhang P, Sun F, Hung H-C, et al. Sensitive and quantitative detection of anti-poly(ethylene glycol) (PEG) antibodies by methoxy-PEG-coated surface plasmon resonance sensors. Anal Chem. 2017;89:8217–8222.
   PubMed Web of Science ®Google Scholar
• Dong H, Mora JR, Brockus C, et al. Development of a generic anti-PEG antibody assay using BioScale’s acoustic membrane microparticle technology. AAPS J. 2015;17:1511–1516.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Lila ASA, Awata M, et al. A cell assay for detecting anti-PEG immune response against PEG-modified therapeutics. Pharm Res. 2018;35:223.
   PubMed Web of Science ®Google Scholar
• Lin WW, Cheng YA, Kao CH, et al. Enhancement effect of a variable topology of a membrane-tethered anti-poly(ethylene glycol) antibody on the sensitivity for quantifying PEG and PEGylated molecules. Anal Chem. 2017;89:6082–6090.
   PubMed Web of Science ®Google Scholar
• Aćimović SS, Šipová-Jungová H, Emilsson G, et al. Antibody–antigen interaction dynamics revealed by analysis of single-molecule equilibrium fluctuations on individual plasmonic nanoparticle biosensors. ACS Nano. 2018;12:9958–9965.
   PubMed Web of Science ®Google Scholar
• Ishida T, Harada M, Wang XY. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Control Release. 2005;105:305–317.
   PubMed Web of Science ®Google Scholar
• McCallen J, Prybylski J, Yang Q, et al. Cross-reactivity of select PEG-binding antibodies to other polymers containing a C-C-O backbone. ACS Biomater Sci Eng. 2017;3:1605–1615.
   PubMed Web of Science ®Google Scholar
• Ando H, Lila ASA, Kawanishi M, et al. Reactivity of IgM antibodies elicited by PEGylated liposomes or PEGylated lipoplex against auto and foreign antigens. J Control Release. 2018;270:114–119.
   PubMed Web of Science ®Google Scholar
• Zhang P, Sun F, Tsao C, et al. Zwitterionic gel encapsulation promotes protein stability, enhances pharmacokinetics, and reduces immunogenicity. Proc Nat Acad Sci. 2015;114:12046–12051.
   Web of Science ®Google Scholar
• Li B, Yuan Z, Zhang P, et al. Zwitterionic nanocages overcome the efficacy loss of biologic drugs. Adv Mater. 2018;30:1705728.
   PubMed Web of Science ®Google Scholar
• Zhang P, Jain P, Tsao C, et al. Polypeptides with high zwitterion density for safe and effective therapeutics. Angew Chem Int Ed. 2018;57:7743–7747.
   PubMed Web of Science ®Google Scholar
• Qi Y, Simakova A, Ganson NJ, et al. A brush-polymer/exendin-4 conjugate reduces blood glucose levels for up to five days and eliminates poly(ethylene glycol) antigenicity. Nat Biomed Eng. 2016;1:0002.
   PubMed Web of Science ®Google Scholar
• Qi Y, Chilkoti A. Protein-polymer conjugation – moving beyond PEGylation. Curr Opin Chem Biol. 2015;28:181–193.
   PubMed Web of Science ®Google Scholar
• Mima Y, Abu Lila AS, Shimizu T, et al. Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity. J Control Release. 2017;250:20–26.
   PubMed Web of Science ®Google Scholar
• Si Y, Liu M, Liang K, et al. Evaluating the accelerated blood clearance phenomenon of PEGylated nanoemulsions in rats by intraperitoneal administration. AAPS PharmSciTech. 2018;19:3210–3218.
   PubMed Web of Science ®Google Scholar